NBE raises CHF20M in series B

NBE-Therapeutics AG (Basel, Switzerland) raised CHF20 million ($20.2 million) in a series B financing led by PPF Group. Boehringer Ingelheim Venture Fund also participated, as did all of the company's existing private investors and one new undisclosed investor.

NBE develops antibody-drug conjugates that do not require mAb mutagenesis or chemical conjugation, which it says reduces the risk of degrading the mAb's structure. All of its programs are preclinical (see BioCentury, June 16, 2014)...